Takeda’s Leading Orexin Franchise Oveporexton Phase 3 Data & Commercial Readiness World Sleep Congress 2025

from the beginning

Takeda’s Leading Orexin Franchise Oveporexton Phase 3 Data & Commercial Readiness World Sleep Congress 2025

Important Notice

Pioneering Orexin science and catalyzing a potential new era of care for patients with narcolepsy type 1 (NT1) with oveporexton

NT1 patients face debilitating daytime and nighttime symptoms often impacting daily function

NT1 pathophysiology is caused by the loss of orexin neurons

Optimized dosing regimen critical to deliver potentially transformative efficacy while minimizing adverse events

Comprehensive approach to evaluate broad spectrum of NT1 symptoms with established and novel endpoints

• Oveporexton Phase 3 Results

Global placebo controlled randomized Oveporexton Ph3 NT1 studies conducted across 19 countries enrolling 273 subjects

Oveporexton could establish a new standard of care in NT1 addressing the broad spectrum of symptoms

Oveporexton significantly improved sleep latency on MWT at 12 weeks with majority of patients within normative range

Oveporexton significantly improved subjective sleepiness at 12 weeks with majority of patients within normative range

Oveporexton significantly reduced weekly cataplexy rate over 12 weeks

Oveporexton demonstrated rapid reduction in cataplexy, sustained over 12 weeks

Oveporexton improved symptoms across NT1 spectrum and reduced the overall symptom severity

Oveporexton improved nighttime symptoms at week 12

Oveporexton significantly improved sustained attention throughout the day with ~70% patients within normative range

Oveporexton significantly improved overall functioning and quality of life

Oveporexton was generally well tolerated

Oveporexton has the potential to establish a new era of care with transformative efficacy

Takeda is pioneering the field of orexin therapeutics with a potentially transformative franchise

• Oveporexton Market Opportunity & Commercialization

No time or energy for what matters most: coping through most aspects of life

Long, exhausting NT1 patient journey is fraught with roadblocks hindering accurate & timely diagnosis, often followed by lifetime of treatment trade-offs

Patients rely on symptomatic treatments, which often lead to persistent breakthrough or residual symptoms and suboptimal disease management

Despite treatment, many patients continue to experience symptoms and need to cope with the continued impact of NT1 on many aspects of their lives

Pioneering a potential paradigm shift with a development program designed to demonstrate the transformative efficacy of an Orexin therapy

Oveporextonis poised to redefine treatment outcomes that matter most to patients

OVEPOREXTON Aspiration:A New Era Of Care

Takeda is leveraging its neuroscience and rare expertise to advance oveporexton towards the market*, preparing for a seamless patient and HCP experience

Successful launch of oveporexton* will unlock the potential of a new era of care in NT1, starting in the US

Takeda is the leader in Orexin biology, aiming to transform patient outcomes

Pioneering Orexin science and catalyzing a potential new era of care for patients with narcolepsy type 1 (NT1) with oveporexton

Q&Atakeda

Q&A

• Q&A1

• Q&A2

• Q&A3

• Q&A4

Glossary of Abbreviations

Medical Presentationas presented at World Sleep 2025

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@